# Intracerebral Hemorrhage and Increased Risk of Arterial Thromboembolism

> **NIH NIH K23** · WEILL MEDICAL COLL OF CORNELL UNIV · 2020 · $194,400

## Abstract

PROJECT SUMMARY/ABSTRACT
 This is a K23 award application for Dr. Santosh Murthy, a neurologist and young investigator pursuing
patient-oriented clinical research on arterial thrombotic events after intracerebral hemorrhage (ICH). Dr. Murthy
intends to develop his skills and expertise in three key areas: 1) advanced biostatistics and data science; 2)
stroke pathophysiology, biomarker analysis, and cardiac diagnostic imaging techniques; and 3) clinical trial
design and implementation. To pursue this project, Dr. Murthy has assembled a mentoring team that
comprises a primary mentor, Dr. Hooman Kamel, a neurologist with expertise in stroke epidemiology and
clinical trial design, and 3 co-mentors, Dr. Costantino Iadecola, a neurologist and neurobiologist with expertise
in ischemic brain injury and biomarkers, Dr. Daniel Hanley, a neurologist with expertise in ICH and clinical trial
design, and Dr. Monika Safford, an internist with expertise in cardiovascular epidemiology. Dr. Murthy's central
hypothesis is that ICH is an independent, short-term, modifiable risk factor for arterial thromboembolism,
defined as acute ischemic stroke or acute myocardial infarction. This hypothesis will be tested by pursuing
three specific aims. Specific Aim 1 will test the hypothesis that the risk of arterial thromboembolism is elevated
in the acute phase after ICH. This will entail performing a cohort study using data pooled from the REasons for
Geographic and Racial Differences in Stroke (REGARDS) study, the Northern Manhattan Study (NOMAS) and
the Strong Heart Study. Specific Aim 2A will test the hypothesis that baseline ICH hematoma volume is
associated with clinically apparent stroke and MI. This will be tested in a secondary analysis of data from the
MISTIE III trial. Specific Aim 2B will test the hypothesis that ICH hematoma volume correlates with magnetic
resonance imaging (MRI) evidence of cerebral and myocardial infarcts. This aim will be tested by performing a
prospective cohort study of ICH patients at New York-Presbyterian Hospital/Weill Cornell. Secondary
exploratory analyses will correlate hematoma volume with known biomarkers of thrombosis. Specific Aim 3 will
test the hypothesis that early use of antithrombotic medications reduces the risk of arterial thromboembolic
events after ICH, even in patients without a high-risk indication for anticoagulation such as atrial fibrillation.
This aim will be pursued by using claims and pharmacy data from Premier, a commercial database containing
data on several thousand ICH hospitalizations across the country. The proposed research is significant
because positive results would uncover ICH as a novel risk factor for subsequent arterial thromboembolic
complications. Furthermore, it would provide crucial preliminary data for a randomized trial to identify optimal
antithrombotic strategies after ICH. The proposed research is innovative because it seeks to shift current
research and clinical practice paradigms by identify...

## Key facts

- **NIH application ID:** 9859473
- **Project number:** 5K23NS105948-03
- **Recipient organization:** WEILL MEDICAL COLL OF CORNELL UNIV
- **Principal Investigator:** Santosh Bhaskar Murthy
- **Activity code:** K23 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $194,400
- **Award type:** 5
- **Project period:** 2018-03-01 → 2023-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9859473

## Citation

> US National Institutes of Health, RePORTER application 9859473, Intracerebral Hemorrhage and Increased Risk of Arterial Thromboembolism (5K23NS105948-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9859473. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*